Stem definition | Drug id | CAS RN |
---|---|---|
bronchodilators, phenethylamine derivatives | 1239 | 73573-87-2 |
Dose | Unit | Route |
---|---|---|
24 | mcg | Inhal.aerosol |
24 | mcg | Inhal.powder |
0.16 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.66 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 8 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.00 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 16, 2001 | FDA | NOVARTIS | |
June 18, 2019 | PMDA | AstraZeneca K.K. | |
April 28, 2014 | EMA | Teva Pharma B.V. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product quality issue | 654.38 | 12.55 | 323 | 26873 | 30535 | 50547393 |
Asthma | 619.31 | 12.55 | 455 | 26741 | 88882 | 50489046 |
Dyspnoea | 445.46 | 12.55 | 933 | 26263 | 546675 | 50031253 |
Wheezing | 283.81 | 12.55 | 248 | 26948 | 61799 | 50516129 |
Cough | 190.81 | 12.55 | 408 | 26788 | 240856 | 50337072 |
Obstructive airways disorder | 189.16 | 12.55 | 113 | 27083 | 15539 | 50562389 |
No adverse event | 177.59 | 12.55 | 146 | 27050 | 33432 | 50544496 |
Chronic obstructive pulmonary disease | 161.40 | 12.55 | 170 | 27026 | 53265 | 50524663 |
Chest discomfort | 154.09 | 12.55 | 218 | 26978 | 92504 | 50485424 |
Product dose omission issue | 135.00 | 12.55 | 302 | 26894 | 183536 | 50394392 |
Polycystic ovaries | 125.33 | 12.55 | 48 | 27148 | 2436 | 50575492 |
Sleep apnoea syndrome | 120.39 | 12.55 | 101 | 27095 | 23767 | 50554161 |
Nasal polyps | 116.96 | 12.55 | 46 | 27150 | 2508 | 50575420 |
Emphysema | 108.16 | 12.55 | 65 | 27131 | 9028 | 50568900 |
Productive cough | 98.16 | 12.55 | 131 | 27065 | 52563 | 50525365 |
Sputum increased | 97.51 | 12.55 | 37 | 27159 | 1830 | 50576098 |
Gastrooesophageal reflux disease | 94.84 | 12.55 | 157 | 27039 | 76271 | 50501657 |
Salpingo-oophorectomy unilateral | 91.13 | 12.55 | 26 | 27170 | 515 | 50577413 |
Sinusitis fungal | 87.15 | 12.55 | 31 | 27165 | 1275 | 50576653 |
Candida infection | 85.93 | 12.55 | 83 | 27113 | 23440 | 50554488 |
Respiratory symptom | 84.96 | 12.55 | 36 | 27160 | 2378 | 50575550 |
Hyper IgE syndrome | 78.27 | 12.55 | 22 | 27174 | 412 | 50577516 |
Embolism venous | 76.89 | 12.55 | 34 | 27162 | 2491 | 50575437 |
Skin candida | 75.52 | 12.55 | 28 | 27168 | 1298 | 50576630 |
Rhinitis allergic | 74.27 | 12.55 | 47 | 27149 | 7153 | 50570775 |
Eczema | 73.47 | 12.55 | 75 | 27121 | 22627 | 50555301 |
Asthmatic crisis | 73.42 | 12.55 | 29 | 27167 | 1599 | 50576329 |
Eosinophilic granulomatosis with polyangiitis | 71.62 | 12.55 | 30 | 27166 | 1925 | 50576003 |
Sensitisation | 67.23 | 12.55 | 27 | 27169 | 1555 | 50576373 |
Female genital tract fistula | 64.83 | 12.55 | 34 | 27162 | 3632 | 50574296 |
Off label use | 64.68 | 12.55 | 97 | 27099 | 474329 | 50103599 |
Ejection fraction | 63.46 | 12.55 | 24 | 27172 | 1176 | 50576752 |
Dysphonia | 60.93 | 12.55 | 89 | 27107 | 38803 | 50539125 |
Systemic lupus erythematosus | 59.91 | 12.55 | 4 | 27192 | 140618 | 50437310 |
Mycobacterium avium complex infection | 58.07 | 12.55 | 28 | 27168 | 2502 | 50575426 |
Blood test abnormal | 57.27 | 12.55 | 48 | 27148 | 11271 | 50566657 |
Bronchospasm | 57.25 | 12.55 | 54 | 27142 | 14800 | 50563128 |
Restrictive pulmonary disease | 56.04 | 12.55 | 23 | 27173 | 1401 | 50576527 |
Chronic sinusitis | 55.73 | 12.55 | 37 | 27159 | 6108 | 50571820 |
Joint swelling | 53.30 | 12.55 | 33 | 27163 | 245253 | 50332675 |
Diastolic dysfunction | 53.16 | 12.55 | 34 | 27162 | 5268 | 50572660 |
Treatment failure | 52.98 | 12.55 | 6 | 27190 | 137631 | 50440297 |
Pneumonia | 51.75 | 12.55 | 364 | 26832 | 378037 | 50199891 |
Toxicity to various agents | 51.37 | 12.55 | 25 | 27171 | 212474 | 50365454 |
Sputum discoloured | 48.41 | 12.55 | 47 | 27149 | 13348 | 50564580 |
Oedema peripheral | 48.17 | 12.55 | 190 | 27006 | 157771 | 50420157 |
Product container issue | 45.93 | 12.55 | 20 | 27176 | 1412 | 50576516 |
Diverticulum | 45.60 | 12.55 | 41 | 27155 | 10573 | 50567355 |
Alopecia | 45.39 | 12.55 | 39 | 27157 | 245008 | 50332920 |
Hepatic enzyme increased | 43.91 | 12.55 | 10 | 27186 | 137370 | 50440558 |
Pulmonary mass | 43.54 | 12.55 | 52 | 27144 | 18653 | 50559275 |
Neurosensory hypoacusis | 43.19 | 12.55 | 12 | 27184 | 215 | 50577713 |
Arthropathy | 42.25 | 12.55 | 16 | 27180 | 157890 | 50420038 |
Pain | 41.86 | 12.55 | 165 | 27031 | 578738 | 49999190 |
Dyspnoea exertional | 41.85 | 12.55 | 88 | 27108 | 51145 | 50526783 |
Drug intolerance | 41.64 | 12.55 | 34 | 27162 | 219070 | 50358858 |
Hiatus hernia | 41.07 | 12.55 | 50 | 27146 | 18294 | 50559634 |
Pulmonary function test decreased | 39.72 | 12.55 | 24 | 27172 | 3364 | 50574564 |
White blood cell count decreased | 38.31 | 12.55 | 8 | 27188 | 116714 | 50461214 |
Peripheral swelling | 37.85 | 12.55 | 33 | 27163 | 205903 | 50372025 |
Facial nerve disorder | 36.58 | 12.55 | 13 | 27183 | 533 | 50577395 |
Feeling jittery | 36.34 | 12.55 | 37 | 27159 | 11123 | 50566805 |
Tricuspid valve incompetence | 35.64 | 12.55 | 39 | 27157 | 12731 | 50565197 |
Rheumatoid arthritis | 35.39 | 12.55 | 34 | 27162 | 202516 | 50375412 |
Bronchiectasis | 35.15 | 12.55 | 35 | 27161 | 10248 | 50567680 |
Hysterectomy | 34.92 | 12.55 | 31 | 27165 | 7859 | 50570069 |
Hypothyroidism | 34.37 | 12.55 | 64 | 27132 | 34061 | 50543867 |
Product use issue | 34.01 | 12.55 | 19 | 27177 | 149456 | 50428472 |
Arthralgia | 33.63 | 12.55 | 122 | 27074 | 438580 | 50139348 |
Rhinitis | 33.57 | 12.55 | 31 | 27165 | 8270 | 50569658 |
Product taste abnormal | 33.20 | 12.55 | 17 | 27179 | 1728 | 50576200 |
CFTR gene mutation | 32.49 | 12.55 | 8 | 27188 | 87 | 50577841 |
Abdominal discomfort | 31.82 | 12.55 | 47 | 27149 | 231594 | 50346334 |
Lipohypertrophy | 31.48 | 12.55 | 12 | 27184 | 601 | 50577327 |
Infusion related reaction | 31.36 | 12.55 | 27 | 27169 | 169530 | 50408398 |
Pulmonary embolism | 29.90 | 12.55 | 121 | 27075 | 101583 | 50476345 |
Underdose | 29.73 | 12.55 | 45 | 27151 | 20233 | 50557695 |
Iron deficiency anaemia | 28.52 | 12.55 | 40 | 27156 | 16794 | 50561134 |
Peak expiratory flow rate decreased | 28.37 | 12.55 | 11 | 27185 | 577 | 50577351 |
Fatigue | 28.35 | 12.55 | 244 | 26952 | 707357 | 49870571 |
Swelling | 28.33 | 12.55 | 40 | 27156 | 200832 | 50377096 |
Transient ischaemic attack | 28.27 | 12.55 | 57 | 27139 | 32153 | 50545775 |
Swollen tongue | 27.96 | 12.55 | 53 | 27143 | 28577 | 50549351 |
Heart rate increased | 27.75 | 12.55 | 98 | 27098 | 77152 | 50500776 |
Osteoporosis | 27.68 | 12.55 | 69 | 27127 | 44810 | 50533118 |
Dyslipidaemia | 27.45 | 12.55 | 24 | 27172 | 5964 | 50571964 |
Bronchitis chronic | 27.32 | 12.55 | 20 | 27176 | 3857 | 50574071 |
Congenital naevus | 27.16 | 12.55 | 8 | 27188 | 178 | 50577750 |
Drug ineffective | 26.75 | 12.55 | 297 | 26899 | 819036 | 49758892 |
Increased upper airway secretion | 26.28 | 12.55 | 18 | 27178 | 3126 | 50574802 |
Increased bronchial secretion | 26.24 | 12.55 | 14 | 27182 | 1548 | 50576380 |
Anaphylactic reaction | 26.18 | 12.55 | 76 | 27120 | 53979 | 50523949 |
Blood electrolytes abnormal | 26.12 | 12.55 | 12 | 27184 | 961 | 50576967 |
Throat tightness | 26.06 | 12.55 | 43 | 27153 | 20804 | 50557124 |
Febrile neutropenia | 25.94 | 12.55 | 10 | 27186 | 97657 | 50480271 |
Throat irritation | 25.93 | 12.55 | 53 | 27143 | 30186 | 50547742 |
Intentional product use issue | 25.80 | 12.55 | 5 | 27191 | 76913 | 50501015 |
Breath sounds abnormal | 25.67 | 12.55 | 26 | 27170 | 7766 | 50570162 |
Breast neoplasm | 25.59 | 12.55 | 13 | 27183 | 1300 | 50576628 |
Musculoskeletal stiffness | 25.58 | 12.55 | 19 | 27177 | 128462 | 50449466 |
Pulmonary congestion | 25.49 | 12.55 | 36 | 27160 | 15211 | 50562717 |
Hypomagnesaemia | 25.31 | 12.55 | 45 | 27151 | 23111 | 50554817 |
Lung neoplasm malignant | 25.06 | 12.55 | 36 | 27160 | 15448 | 50562480 |
Drug hypersensitivity | 24.80 | 12.55 | 62 | 27134 | 250948 | 50326980 |
Nephrectomy | 24.64 | 12.55 | 11 | 27185 | 824 | 50577104 |
Circumstance or information capable of leading to medication error | 23.73 | 12.55 | 17 | 27179 | 3171 | 50574757 |
Sleep disorder due to a general medical condition | 23.20 | 12.55 | 24 | 27172 | 7347 | 50570581 |
Skin lesion | 23.10 | 12.55 | 47 | 27149 | 26680 | 50551248 |
Diarrhoea | 22.61 | 12.55 | 205 | 26991 | 588271 | 49989657 |
Nervous system disorder | 22.38 | 12.55 | 35 | 27161 | 16188 | 50561740 |
Middle insomnia | 22.14 | 12.55 | 27 | 27169 | 9894 | 50568034 |
Disease recurrence | 21.91 | 12.55 | 39 | 27157 | 20042 | 50557886 |
Female reproductive neoplasm | 21.91 | 12.55 | 5 | 27191 | 38 | 50577890 |
Pharyngeal oedema | 21.89 | 12.55 | 31 | 27165 | 13134 | 50564794 |
Glossodynia | 21.85 | 12.55 | 18 | 27178 | 115551 | 50462377 |
Incorrect dose administered | 21.48 | 12.55 | 66 | 27130 | 48348 | 50529580 |
Device malfunction | 21.38 | 12.55 | 33 | 27163 | 15088 | 50562840 |
Therapeutic product effect decreased | 21.33 | 12.55 | 25 | 27171 | 136025 | 50441903 |
Peripheral vascular disorder | 21.30 | 12.55 | 20 | 27176 | 5447 | 50572481 |
Palpitations | 20.67 | 12.55 | 103 | 27093 | 94403 | 50483525 |
Impaired healing | 20.53 | 12.55 | 6 | 27190 | 69780 | 50508148 |
Angioplasty | 20.39 | 12.55 | 11 | 27185 | 1244 | 50576684 |
Discomfort | 20.34 | 12.55 | 17 | 27179 | 108363 | 50469565 |
Neutropenic sepsis | 20.18 | 12.55 | 31 | 27165 | 14116 | 50563812 |
Therapy partial responder | 19.92 | 12.55 | 21 | 27175 | 6570 | 50571358 |
Drug abuse | 19.84 | 12.55 | 4 | 27192 | 59842 | 50518086 |
Foreign body aspiration | 19.79 | 12.55 | 6 | 27190 | 148 | 50577780 |
Macrocytosis | 19.74 | 12.55 | 13 | 27183 | 2117 | 50575811 |
Coronary artery disease | 19.71 | 12.55 | 47 | 27149 | 29679 | 50548249 |
Device ineffective | 19.67 | 12.55 | 6 | 27190 | 151 | 50577777 |
Bordetella test positive | 19.59 | 12.55 | 3 | 27193 | 0 | 50577928 |
Carnitine deficiency | 19.56 | 12.55 | 6 | 27190 | 154 | 50577774 |
Respiratory tract infection | 19.51 | 12.55 | 49 | 27147 | 31968 | 50545960 |
Burning sensation | 19.28 | 12.55 | 61 | 27135 | 45385 | 50532543 |
Tubulointerstitial nephritis and uveitis syndrome | 19.00 | 12.55 | 6 | 27190 | 170 | 50577758 |
Hypertension | 18.97 | 12.55 | 185 | 27011 | 211018 | 50366910 |
Kyphosis | 18.85 | 12.55 | 13 | 27183 | 2282 | 50575646 |
Infective exacerbation of chronic obstructive airways disease | 18.81 | 12.55 | 10 | 27186 | 1098 | 50576830 |
Oligohydramnios | 18.60 | 12.55 | 19 | 27177 | 5731 | 50572197 |
Cardiac disorder | 18.52 | 12.55 | 58 | 27138 | 42921 | 50535007 |
Allergic sinusitis | 18.29 | 12.55 | 8 | 27188 | 571 | 50577357 |
Spirometry abnormal | 17.87 | 12.55 | 6 | 27190 | 207 | 50577721 |
Oropharyngeal pain | 17.87 | 12.55 | 86 | 27110 | 77715 | 50500213 |
Fungal infection | 17.36 | 12.55 | 45 | 27151 | 29920 | 50548008 |
Choking | 17.16 | 12.55 | 22 | 27174 | 8476 | 50569452 |
Infection | 16.85 | 12.55 | 43 | 27153 | 172911 | 50405017 |
Disease progression | 16.83 | 12.55 | 16 | 27180 | 95850 | 50482078 |
Oedema mouth | 16.56 | 12.55 | 12 | 27184 | 2278 | 50575650 |
Lip pruritus | 16.38 | 12.55 | 8 | 27188 | 735 | 50577193 |
Restless legs syndrome | 16.23 | 12.55 | 30 | 27166 | 15867 | 50562061 |
Deep vein thrombosis | 16.10 | 12.55 | 80 | 27116 | 73224 | 50504704 |
Pancreatitis relapsing | 16.04 | 12.55 | 8 | 27188 | 769 | 50577159 |
Mobility decreased | 15.68 | 12.55 | 12 | 27184 | 79936 | 50497992 |
Limb injury | 15.63 | 12.55 | 34 | 27162 | 20216 | 50557712 |
Intentional overdose | 15.63 | 12.55 | 7 | 27189 | 62497 | 50515431 |
Bronchopulmonary aspergillosis allergic | 15.43 | 12.55 | 9 | 27187 | 1182 | 50576746 |
Depression | 15.39 | 12.55 | 146 | 27050 | 165277 | 50412651 |
Eosinophilia | 15.18 | 12.55 | 32 | 27164 | 18620 | 50559308 |
Oral candidiasis | 14.92 | 12.55 | 30 | 27166 | 16885 | 50561043 |
Presbyacusis | 14.51 | 12.55 | 12 | 27184 | 2764 | 50575164 |
Lip swelling | 14.18 | 12.55 | 37 | 27159 | 24699 | 50553229 |
Mouth ulceration | 14.14 | 12.55 | 40 | 27156 | 27984 | 50549944 |
Blood immunoglobulin E increased | 14.04 | 12.55 | 11 | 27185 | 2348 | 50575580 |
Nasal inflammation | 13.98 | 12.55 | 6 | 27190 | 409 | 50577519 |
Left ventricular hypertrophy | 13.87 | 12.55 | 15 | 27181 | 4830 | 50573098 |
Urinary retention | 13.83 | 12.55 | 38 | 27158 | 26152 | 50551776 |
Long QT syndrome | 13.82 | 12.55 | 12 | 27184 | 2955 | 50574973 |
Malignant neoplasm progression | 13.65 | 12.55 | 10 | 27186 | 68114 | 50509814 |
Chest pain | 13.54 | 12.55 | 150 | 27046 | 176732 | 50401196 |
Myocardial infarction | 13.50 | 12.55 | 88 | 27108 | 88939 | 50488989 |
Neutropenia | 13.49 | 12.55 | 38 | 27158 | 147927 | 50430001 |
Bronchitis | 13.46 | 12.55 | 99 | 27097 | 104060 | 50473868 |
Abscess | 13.42 | 12.55 | 26 | 27170 | 14246 | 50563682 |
Haemoptysis | 13.40 | 12.55 | 37 | 27159 | 25536 | 50552392 |
Laryngeal oedema | 13.35 | 12.55 | 15 | 27181 | 5038 | 50572890 |
Platelet count decreased | 13.27 | 12.55 | 21 | 27175 | 100705 | 50477223 |
Essential hypertension | 13.15 | 12.55 | 14 | 27182 | 4430 | 50573498 |
Product dosage form issue | 13.12 | 12.55 | 3 | 27193 | 23 | 50577905 |
Tremor | 13.06 | 12.55 | 106 | 27090 | 114797 | 50463131 |
Blister | 13.06 | 12.55 | 16 | 27180 | 85402 | 50492526 |
Haemorrhage | 12.94 | 12.55 | 60 | 27136 | 53381 | 50524547 |
Hypotension | 12.89 | 12.55 | 74 | 27122 | 235395 | 50342533 |
Renal disorder | 12.67 | 12.55 | 38 | 27158 | 27467 | 50550461 |
Carpal tunnel syndrome | 12.62 | 12.55 | 28 | 27168 | 16865 | 50561063 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product quality issue | 406.52 | 14.05 | 188 | 15377 | 15707 | 29543255 |
Asthma | 352.13 | 14.05 | 220 | 15345 | 33629 | 29525333 |
Dyspnoea | 259.01 | 14.05 | 544 | 15021 | 326188 | 29232774 |
No adverse event | 167.53 | 14.05 | 108 | 15457 | 17370 | 29541592 |
Nasal obstruction | 157.27 | 14.05 | 40 | 15525 | 513 | 29558449 |
Wheezing | 138.67 | 14.05 | 125 | 15440 | 33115 | 29525847 |
Chronic obstructive pulmonary disease | 136.50 | 14.05 | 136 | 15429 | 40819 | 29518143 |
Sinus pain | 120.72 | 14.05 | 33 | 15532 | 568 | 29558394 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 113.80 | 14.05 | 33 | 15532 | 710 | 29558252 |
Eosinophilic granulomatosis with polyangiitis | 93.56 | 14.05 | 33 | 15532 | 1353 | 29557609 |
Pulmonary function test decreased | 87.25 | 14.05 | 43 | 15522 | 4120 | 29554842 |
Emphysema | 86.55 | 14.05 | 55 | 15510 | 8616 | 29550346 |
Cough | 84.70 | 14.05 | 198 | 15367 | 126529 | 29432433 |
Throat irritation | 80.97 | 14.05 | 53 | 15512 | 8732 | 29550230 |
Mycobacterium avium complex infection | 77.76 | 14.05 | 33 | 15532 | 2236 | 29556726 |
Product dose omission issue | 74.91 | 14.05 | 160 | 15405 | 96223 | 29462739 |
Bronchiectasis | 73.89 | 14.05 | 45 | 15520 | 6540 | 29552422 |
Chest discomfort | 63.44 | 14.05 | 98 | 15467 | 45885 | 29513077 |
Hepatic vein dilatation | 62.14 | 14.05 | 16 | 15549 | 216 | 29558746 |
Sputum discoloured | 61.47 | 14.05 | 40 | 15525 | 6523 | 29552439 |
Eosinophil count | 60.25 | 14.05 | 14 | 15551 | 119 | 29558843 |
Vocal cord dysfunction | 57.51 | 14.05 | 14 | 15551 | 148 | 29558814 |
Osteopenia | 55.99 | 14.05 | 32 | 15533 | 4136 | 29554826 |
Liver palpable | 53.98 | 14.05 | 15 | 15550 | 275 | 29558687 |
Lung consolidation | 52.86 | 14.05 | 33 | 15532 | 5010 | 29553952 |
Respiratory disorder | 52.13 | 14.05 | 54 | 15511 | 16929 | 29542033 |
Obstructive airways disorder | 49.00 | 14.05 | 43 | 15522 | 10973 | 29547989 |
Suffocation feeling | 48.73 | 14.05 | 16 | 15549 | 526 | 29558436 |
Atrial enlargement | 47.30 | 14.05 | 14 | 15551 | 324 | 29558638 |
Ventricular enlargement | 42.93 | 14.05 | 14 | 15551 | 450 | 29558512 |
Toxicity to various agents | 42.72 | 14.05 | 19 | 15546 | 173642 | 29385320 |
Pulmonary mass | 41.99 | 14.05 | 39 | 15526 | 10709 | 29548253 |
Inferior vena cava dilatation | 41.46 | 14.05 | 15 | 15550 | 662 | 29558300 |
Dyspnoea at rest | 41.37 | 14.05 | 24 | 15541 | 3190 | 29555772 |
Nasal congestion | 40.78 | 14.05 | 50 | 15515 | 18829 | 29540133 |
Hangover | 39.53 | 14.05 | 16 | 15549 | 961 | 29558001 |
Panic reaction | 38.12 | 14.05 | 17 | 15548 | 1298 | 29557664 |
Sputum increased | 37.70 | 14.05 | 19 | 15546 | 1908 | 29557054 |
Chest pain | 34.37 | 14.05 | 133 | 15432 | 111840 | 29447122 |
Sleep disorder due to a general medical condition | 31.50 | 14.05 | 20 | 15545 | 3126 | 29555836 |
Bronchial obstruction | 31.04 | 14.05 | 15 | 15550 | 1376 | 29557586 |
Bronchial hyperreactivity | 30.88 | 14.05 | 15 | 15550 | 1391 | 29557571 |
Bronchospasm | 30.29 | 14.05 | 31 | 15534 | 9578 | 29549384 |
Toxic neuropathy | 28.23 | 14.05 | 10 | 15555 | 415 | 29558547 |
Stridor | 26.76 | 14.05 | 16 | 15549 | 2247 | 29556715 |
Fungal oesophagitis | 26.76 | 14.05 | 9 | 15556 | 319 | 29558643 |
Full blood count abnormal | 26.52 | 14.05 | 36 | 15529 | 14977 | 29543985 |
Weaning failure | 25.82 | 14.05 | 8 | 15557 | 217 | 29558745 |
Rales | 25.08 | 14.05 | 25 | 15540 | 7485 | 29551477 |
Underdose | 24.93 | 14.05 | 31 | 15534 | 11838 | 29547124 |
Product container issue | 24.92 | 14.05 | 10 | 15555 | 587 | 29558375 |
Foreign body aspiration | 23.99 | 14.05 | 7 | 15558 | 154 | 29558808 |
Oedema mouth | 23.96 | 14.05 | 12 | 15553 | 1189 | 29557773 |
Forced expiratory volume decreased | 23.57 | 14.05 | 16 | 15549 | 2797 | 29556165 |
Oedema | 23.48 | 14.05 | 60 | 15505 | 40423 | 29518539 |
Heart rate irregular | 22.48 | 14.05 | 31 | 15534 | 13086 | 29545876 |
Cardiac failure chronic | 22.47 | 14.05 | 22 | 15543 | 6445 | 29552517 |
Pneumonia | 22.43 | 14.05 | 262 | 15303 | 319910 | 29239052 |
Spontaneous haemorrhage | 22.35 | 14.05 | 7 | 15558 | 197 | 29558765 |
Nasal polyps | 22.21 | 14.05 | 13 | 15552 | 1756 | 29557206 |
Platelet count decreased | 21.97 | 14.05 | 14 | 15551 | 104658 | 29454304 |
Cockroach allergy | 21.90 | 14.05 | 5 | 15560 | 39 | 29558923 |
Palpitations | 21.75 | 14.05 | 51 | 15514 | 32553 | 29526409 |
Breath sounds abnormal | 21.70 | 14.05 | 20 | 15545 | 5437 | 29553525 |
Bronchial disorder | 21.41 | 14.05 | 11 | 15554 | 1150 | 29557812 |
Drug abuse | 20.81 | 14.05 | 8 | 15557 | 79875 | 29479087 |
Adrenal cortex necrosis | 20.66 | 14.05 | 4 | 15561 | 12 | 29558950 |
Orthostatic intolerance | 20.62 | 14.05 | 9 | 15556 | 653 | 29558309 |
Neutropenia | 19.93 | 14.05 | 24 | 15541 | 131687 | 29427275 |
Product taste abnormal | 19.54 | 14.05 | 10 | 15555 | 1037 | 29557925 |
Necrotising ulcerative gingivostomatitis | 19.25 | 14.05 | 5 | 15560 | 70 | 29558892 |
Nasal turbinate hypertrophy | 18.69 | 14.05 | 5 | 15560 | 79 | 29558883 |
Dysphonia | 18.61 | 14.05 | 35 | 15530 | 19161 | 29539801 |
Circumstance or information capable of leading to medication error | 18.61 | 14.05 | 11 | 15554 | 1513 | 29557449 |
Rebound effect | 18.09 | 14.05 | 12 | 15553 | 2019 | 29556943 |
Pulmonary congestion | 17.82 | 14.05 | 27 | 15538 | 12409 | 29546553 |
Product prescribing error | 17.71 | 14.05 | 33 | 15532 | 17943 | 29541019 |
Diarrhoea | 17.61 | 14.05 | 103 | 15462 | 332595 | 29226367 |
Therapeutic product effect incomplete | 17.58 | 14.05 | 53 | 15512 | 39252 | 29519710 |
Laryngeal cryptococcosis | 17.57 | 14.05 | 3 | 15562 | 3 | 29558959 |
Complicated appendicitis | 17.21 | 14.05 | 4 | 15561 | 34 | 29558928 |
Paradoxical drug reaction | 17.03 | 14.05 | 13 | 15552 | 2728 | 29556234 |
Death | 17.01 | 14.05 | 108 | 15457 | 341976 | 29216986 |
Nocturnal dyspnoea | 16.52 | 14.05 | 7 | 15558 | 472 | 29558490 |
Aortic dissection | 16.36 | 14.05 | 12 | 15553 | 2372 | 29556590 |
Aphonia | 16.25 | 14.05 | 13 | 15552 | 2921 | 29556041 |
Coronary artery stenosis | 15.81 | 14.05 | 21 | 15544 | 8552 | 29550410 |
Paranasal sinus mucosal hypertrophy | 14.90 | 14.05 | 4 | 15561 | 64 | 29558898 |
Productive cough | 14.79 | 14.05 | 43 | 15522 | 31216 | 29527746 |
Incorrect dose administered | 14.31 | 14.05 | 44 | 15521 | 32940 | 29526022 |
Dyspnoea exertional | 14.29 | 14.05 | 47 | 15518 | 36443 | 29522519 |
Arthritis allergic | 14.28 | 14.05 | 3 | 15562 | 15 | 29558947 |
Oedema peripheral | 14.06 | 14.05 | 98 | 15467 | 103459 | 29455503 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 572.21 | 12.00 | 434 | 32052 | 94791 | 64371455 |
Dyspnoea | 447.44 | 12.00 | 1059 | 31427 | 717615 | 63748631 |
Wheezing | 275.48 | 12.00 | 266 | 32220 | 80313 | 64385933 |
Product quality issue | 253.14 | 12.00 | 168 | 32318 | 29631 | 64436615 |
Cough | 212.61 | 12.00 | 469 | 32017 | 301679 | 64164567 |
Chronic obstructive pulmonary disease | 189.05 | 12.00 | 205 | 32281 | 70843 | 64395403 |
Emphysema | 161.40 | 12.00 | 96 | 32390 | 13973 | 64452273 |
Obstructive airways disorder | 157.59 | 12.00 | 114 | 32372 | 23071 | 64443175 |
Eosinophilic granulomatosis with polyangiitis | 157.39 | 12.00 | 58 | 32428 | 2824 | 64463422 |
Chest discomfort | 143.90 | 12.00 | 230 | 32256 | 115876 | 64350370 |
Polycystic ovaries | 135.00 | 12.00 | 48 | 32438 | 2107 | 64464139 |
Sleep apnoea syndrome | 128.15 | 12.00 | 112 | 32374 | 29720 | 64436526 |
Nasal polyps | 123.97 | 12.00 | 52 | 32434 | 3577 | 64462669 |
Sputum increased | 113.93 | 12.00 | 49 | 32437 | 3586 | 64462660 |
Productive cough | 94.75 | 12.00 | 148 | 32338 | 73055 | 64393191 |
Gastrooesophageal reflux disease | 92.56 | 12.00 | 157 | 32329 | 82986 | 64383260 |
Pulmonary function test decreased | 89.89 | 12.00 | 50 | 32436 | 6411 | 64459835 |
Nasal obstruction | 87.90 | 12.00 | 31 | 32455 | 1328 | 64464918 |
Sputum discoloured | 86.83 | 12.00 | 72 | 32414 | 17784 | 64448462 |
Salpingo-oophorectomy unilateral | 85.82 | 12.00 | 24 | 32462 | 472 | 64465774 |
Toxicity to various agents | 82.56 | 12.00 | 40 | 32446 | 363473 | 64102773 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 81.79 | 12.00 | 28 | 32458 | 1097 | 64465149 |
Hyper IgE syndrome | 76.82 | 12.00 | 22 | 32464 | 473 | 64465773 |
Respiratory symptom | 75.93 | 12.00 | 35 | 32451 | 3018 | 64463228 |
Sinusitis fungal | 73.92 | 12.00 | 29 | 32457 | 1677 | 64464569 |
Bronchospasm | 71.02 | 12.00 | 70 | 32416 | 21612 | 64444634 |
Skin candida | 70.47 | 12.00 | 28 | 32458 | 1675 | 64464571 |
Rhinitis allergic | 69.66 | 12.00 | 46 | 32440 | 8032 | 64458214 |
Female genital tract fistula | 67.76 | 12.00 | 31 | 32455 | 2627 | 64463619 |
Bronchiectasis | 66.64 | 12.00 | 56 | 32430 | 14084 | 64452162 |
Sensitisation | 66.57 | 12.00 | 27 | 32459 | 1704 | 64464542 |
Ejection fraction | 63.35 | 12.00 | 24 | 32462 | 1262 | 64464984 |
Embolism venous | 62.48 | 12.00 | 32 | 32454 | 3475 | 64462771 |
Completed suicide | 60.29 | 12.00 | 19 | 32467 | 224395 | 64241851 |
Asthmatic crisis | 59.44 | 12.00 | 25 | 32461 | 1731 | 64464515 |
Eczema | 59.28 | 12.00 | 74 | 32412 | 29646 | 64436600 |
Eosinophil count | 57.10 | 12.00 | 13 | 32473 | 105 | 64466141 |
Hepatic vein dilatation | 56.95 | 12.00 | 15 | 32471 | 233 | 64466013 |
Candida infection | 56.02 | 12.00 | 74 | 32412 | 31345 | 64434901 |
Blood test abnormal | 54.38 | 12.00 | 48 | 32438 | 12895 | 64453351 |
Sinus pain | 53.12 | 12.00 | 26 | 32460 | 2563 | 64463683 |
Chronic sinusitis | 52.25 | 12.00 | 35 | 32451 | 6257 | 64459989 |
Liver palpable | 51.96 | 12.00 | 15 | 32471 | 332 | 64465914 |
Oedema peripheral | 49.89 | 12.00 | 224 | 32262 | 210093 | 64256153 |
Restrictive pulmonary disease | 48.15 | 12.00 | 23 | 32463 | 2149 | 64464097 |
Breath sounds abnormal | 46.49 | 12.00 | 42 | 32444 | 11627 | 64454619 |
Throat irritation | 46.34 | 12.00 | 69 | 32417 | 32642 | 64433604 |
Pneumonia | 45.72 | 12.00 | 456 | 32030 | 559120 | 63907126 |
Dyspnoea exertional | 45.58 | 12.00 | 109 | 32377 | 73621 | 64392625 |
Neurosensory hypoacusis | 44.12 | 12.00 | 12 | 32474 | 212 | 64466034 |
Dysphonia | 43.13 | 12.00 | 81 | 32405 | 46301 | 64419945 |
Off label use | 42.85 | 12.00 | 169 | 32317 | 632637 | 63833609 |
Ventricular enlargement | 41.89 | 12.00 | 14 | 32472 | 509 | 64465737 |
Diastolic dysfunction | 41.51 | 12.00 | 35 | 32451 | 8840 | 64457406 |
Vocal cord dysfunction | 40.60 | 12.00 | 13 | 32473 | 412 | 64465834 |
Inferior vena cava dilatation | 40.53 | 12.00 | 15 | 32471 | 739 | 64465507 |
Mycobacterium avium complex infection | 40.33 | 12.00 | 25 | 32461 | 3915 | 64462331 |
Feeling jittery | 39.88 | 12.00 | 37 | 32449 | 10598 | 64455648 |
Joint swelling | 38.74 | 12.00 | 31 | 32455 | 215351 | 64250895 |
Atrial enlargement | 38.70 | 12.00 | 14 | 32472 | 646 | 64465600 |
Drug abuse | 37.75 | 12.00 | 10 | 32476 | 132364 | 64333882 |
Pulmonary mass | 37.43 | 12.00 | 53 | 32433 | 23963 | 64442283 |
Hysterectomy | 36.83 | 12.00 | 26 | 32460 | 5059 | 64461187 |
Intentional product use issue | 36.74 | 12.00 | 3 | 32483 | 95361 | 64370885 |
Febrile neutropenia | 36.34 | 12.00 | 25 | 32461 | 187632 | 64278614 |
Osteoporosis | 36.07 | 12.00 | 71 | 32415 | 42009 | 64424237 |
Respiratory disorder | 36.01 | 12.00 | 65 | 32421 | 36046 | 64430200 |
Diverticulum | 34.91 | 12.00 | 38 | 32448 | 13160 | 64453086 |
Facial nerve disorder | 34.79 | 12.00 | 13 | 32473 | 658 | 64465588 |
Product container issue | 34.02 | 12.00 | 14 | 32472 | 917 | 64465329 |
Dyspnoea at rest | 33.88 | 12.00 | 27 | 32459 | 6302 | 64459944 |
Tricuspid valve incompetence | 33.37 | 12.00 | 42 | 32444 | 16961 | 64449285 |
Chest pain | 33.24 | 12.00 | 218 | 32268 | 235762 | 64230484 |
Hypothyroidism | 33.16 | 12.00 | 67 | 32419 | 40390 | 64425856 |
Suffocation feeling | 32.87 | 12.00 | 16 | 32470 | 1558 | 64464688 |
Hiatus hernia | 32.52 | 12.00 | 45 | 32441 | 19912 | 64446334 |
Breast neoplasm | 31.72 | 12.00 | 13 | 32473 | 843 | 64465403 |
Swollen tongue | 31.20 | 12.00 | 60 | 32426 | 34894 | 64431352 |
Arthropathy | 31.14 | 12.00 | 11 | 32475 | 120956 | 64345290 |
Lung consolidation | 31.06 | 12.00 | 28 | 32458 | 7730 | 64458516 |
Hangover | 30.02 | 12.00 | 16 | 32470 | 1885 | 64464361 |
Product use issue | 29.65 | 12.00 | 20 | 32466 | 151695 | 64314551 |
Bronchial obstruction | 29.33 | 12.00 | 17 | 32469 | 2357 | 64463889 |
Lipohypertrophy | 29.25 | 12.00 | 12 | 32474 | 780 | 64465466 |
Platelet count decreased | 29.09 | 12.00 | 25 | 32461 | 167686 | 64298560 |
CFTR gene mutation | 28.89 | 12.00 | 7 | 32479 | 76 | 64466170 |
Bronchitis chronic | 28.23 | 12.00 | 20 | 32466 | 3912 | 64462334 |
White blood cell count decreased | 28.02 | 12.00 | 23 | 32463 | 157814 | 64308432 |
Pain | 27.45 | 12.00 | 165 | 32321 | 553346 | 63912900 |
Contraindicated product administered | 27.42 | 12.00 | 10 | 32476 | 107819 | 64358427 |
Stridor | 26.54 | 12.00 | 21 | 32465 | 4853 | 64461393 |
Eosinophilia | 26.51 | 12.00 | 59 | 32427 | 38017 | 64428229 |
Increased bronchial secretion | 26.50 | 12.00 | 17 | 32469 | 2825 | 64463421 |
Pulmonary congestion | 26.42 | 12.00 | 45 | 32441 | 23835 | 64442411 |
Treatment failure | 26.24 | 12.00 | 13 | 32473 | 116803 | 64349443 |
Sleep disorder due to a general medical condition | 25.88 | 12.00 | 26 | 32460 | 8208 | 64458038 |
Bronchial disorder | 25.74 | 12.00 | 15 | 32471 | 2100 | 64464146 |
Peripheral swelling | 25.72 | 12.00 | 41 | 32445 | 209112 | 64257134 |
Nasal congestion | 25.54 | 12.00 | 77 | 32409 | 59581 | 64406665 |
Increased upper airway secretion | 25.46 | 12.00 | 18 | 32468 | 3509 | 64462737 |
Full blood count abnormal | 25.25 | 12.00 | 50 | 32436 | 29707 | 64436539 |
Peak expiratory flow rate decreased | 24.85 | 12.00 | 10 | 32476 | 618 | 64465628 |
Musculoskeletal stiffness | 24.40 | 12.00 | 16 | 32470 | 123190 | 64343056 |
Rales | 24.31 | 12.00 | 34 | 32452 | 15195 | 64451051 |
Foreign body aspiration | 24.23 | 12.00 | 8 | 32478 | 280 | 64465966 |
Neutropenia | 24.15 | 12.00 | 53 | 32433 | 239571 | 64226675 |
Alopecia | 23.85 | 12.00 | 29 | 32457 | 165661 | 64300585 |
Transient ischaemic attack | 23.81 | 12.00 | 62 | 32424 | 44120 | 64422126 |
Palpitations | 23.78 | 12.00 | 110 | 32376 | 104378 | 64361868 |
Pulmonary embolism | 23.58 | 12.00 | 140 | 32346 | 146216 | 64320030 |
Disease progression | 23.51 | 12.00 | 22 | 32464 | 141658 | 64324588 |
Cockroach allergy | 23.36 | 12.00 | 6 | 32480 | 84 | 64466162 |
Peripheral vascular disorder | 22.96 | 12.00 | 23 | 32463 | 7238 | 64459008 |
Diarrhoea | 22.63 | 12.00 | 244 | 32242 | 722460 | 63743786 |
Toxic neuropathy | 22.57 | 12.00 | 10 | 32476 | 786 | 64465460 |
Nephrectomy | 22.54 | 12.00 | 12 | 32474 | 1410 | 64464836 |
Fungal oesophagitis | 22.53 | 12.00 | 10 | 32476 | 789 | 64465457 |
Rheumatoid arthritis | 22.35 | 12.00 | 30 | 32456 | 164264 | 64301982 |
Pharyngeal oedema | 22.34 | 12.00 | 33 | 32453 | 15498 | 64450748 |
Rebound effect | 22.20 | 12.00 | 19 | 32467 | 4898 | 64461348 |
Rhinitis | 21.77 | 12.00 | 27 | 32459 | 10738 | 64455508 |
Oedema mouth | 21.53 | 12.00 | 15 | 32471 | 2858 | 64463388 |
Pericarditis | 21.45 | 12.00 | 3 | 32483 | 62513 | 64403733 |
Product dose omission issue | 21.11 | 12.00 | 169 | 32317 | 194578 | 64271668 |
Bronchial hyperreactivity | 20.92 | 12.00 | 14 | 32472 | 2498 | 64463748 |
Angioplasty | 20.64 | 12.00 | 12 | 32474 | 1673 | 64464573 |
Lung neoplasm malignant | 20.61 | 12.00 | 38 | 32448 | 21410 | 64444836 |
Infusion related reaction | 20.44 | 12.00 | 32 | 32454 | 164435 | 64301811 |
Heart rate increased | 20.36 | 12.00 | 101 | 32385 | 98574 | 64367672 |
Forced expiratory volume decreased | 20.34 | 12.00 | 21 | 32465 | 6846 | 64459400 |
Adrenal cortex necrosis | 20.15 | 12.00 | 4 | 32482 | 15 | 64466231 |
Systemic lupus erythematosus | 20.07 | 12.00 | 7 | 32479 | 77605 | 64388641 |
Blood electrolytes abnormal | 19.96 | 12.00 | 12 | 32474 | 1779 | 64464467 |
Bordetella test positive | 19.78 | 12.00 | 3 | 32483 | 0 | 64466246 |
Throat tightness | 19.75 | 12.00 | 39 | 32447 | 23121 | 64443125 |
Oropharyngeal pain | 19.08 | 12.00 | 92 | 32394 | 88775 | 64377471 |
Macrocytosis | 18.84 | 12.00 | 13 | 32473 | 2439 | 64463807 |
Product taste abnormal | 18.72 | 12.00 | 12 | 32474 | 1991 | 64464255 |
Drug intolerance | 18.59 | 12.00 | 42 | 32444 | 187950 | 64278296 |
Dyslipidaemia | 18.40 | 12.00 | 23 | 32463 | 9219 | 64457027 |
Carnitine deficiency | 18.36 | 12.00 | 6 | 32480 | 203 | 64466043 |
Syncope | 18.30 | 12.00 | 139 | 32347 | 157496 | 64308750 |
Weaning failure | 18.19 | 12.00 | 8 | 32478 | 618 | 64465628 |
Middle insomnia | 18 | 12.00 | 27 | 32459 | 12850 | 64453396 |
Anosmia | 17.80 | 12.00 | 16 | 32470 | 4401 | 64461845 |
Laryngeal cryptococcosis | 17.70 | 12.00 | 3 | 32483 | 3 | 64466243 |
Nervous system disorder | 17.48 | 12.00 | 37 | 32449 | 23041 | 64443205 |
Spontaneous haemorrhage | 17.45 | 12.00 | 7 | 32479 | 429 | 64465817 |
Skin lesion | 17.45 | 12.00 | 49 | 32437 | 36433 | 64429813 |
Essential hypertension | 17.44 | 12.00 | 17 | 32469 | 5177 | 64461069 |
Hepatic enzyme increased | 17.40 | 12.00 | 24 | 32462 | 129919 | 64336327 |
Circumstance or information capable of leading to medication error | 17.35 | 12.00 | 14 | 32472 | 3326 | 64462920 |
Cardiac failure chronic | 17.21 | 12.00 | 22 | 32464 | 9019 | 64457227 |
Panic reaction | 17.04 | 12.00 | 15 | 32471 | 4012 | 64462234 |
Pyrexia | 16.90 | 12.00 | 190 | 32296 | 558454 | 63907792 |
Lower respiratory tract infection | 16.87 | 12.00 | 93 | 32393 | 94521 | 64371725 |
Allergic sinusitis | 16.83 | 12.00 | 7 | 32479 | 471 | 64465775 |
Kyphosis | 16.79 | 12.00 | 12 | 32474 | 2381 | 64463865 |
Hypomagnesaemia | 16.71 | 12.00 | 49 | 32437 | 37327 | 64428919 |
Tubulointerstitial nephritis and uveitis syndrome | 16.56 | 12.00 | 6 | 32480 | 278 | 64465968 |
Sepsis | 16.50 | 12.00 | 60 | 32426 | 230281 | 64235965 |
Iron deficiency anaemia | 16.47 | 12.00 | 35 | 32451 | 21854 | 64444392 |
Lip swelling | 16.40 | 12.00 | 44 | 32442 | 31863 | 64434383 |
Crepitations | 16.25 | 12.00 | 20 | 32466 | 7895 | 64458351 |
Infection | 16.17 | 12.00 | 44 | 32442 | 184836 | 64281410 |
Urinary retention | 16.12 | 12.00 | 58 | 32428 | 49143 | 64417103 |
Complicated appendicitis | 16.07 | 12.00 | 4 | 32482 | 49 | 64466197 |
Presbyacusis | 16.00 | 12.00 | 12 | 32474 | 2563 | 64463683 |
Limb injury | 15.89 | 12.00 | 36 | 32450 | 23469 | 64442777 |
Bronchopulmonary aspergillosis allergic | 15.87 | 12.00 | 10 | 32476 | 1612 | 64464634 |
Encephalopathy | 15.74 | 12.00 | 5 | 32481 | 58814 | 64407432 |
Sinusitis | 15.46 | 12.00 | 126 | 32360 | 145802 | 64320444 |
Anaphylactic reaction | 15.40 | 12.00 | 72 | 32414 | 68592 | 64397654 |
Heart rate irregular | 15.31 | 12.00 | 39 | 32447 | 27374 | 64438872 |
Cushingoid | 15.27 | 12.00 | 19 | 32467 | 7584 | 64458662 |
Nasal inflammation | 15.26 | 12.00 | 7 | 32479 | 597 | 64465649 |
Cardiac disorder | 15.17 | 12.00 | 62 | 32424 | 55754 | 64410492 |
Carpal tunnel syndrome | 15.15 | 12.00 | 28 | 32458 | 15800 | 64450446 |
Coronary artery stenosis | 14.90 | 12.00 | 23 | 32463 | 11225 | 64455021 |
Aortic dissection | 14.89 | 12.00 | 13 | 32473 | 3439 | 64462807 |
Status asthmaticus | 14.87 | 12.00 | 8 | 32478 | 960 | 64465286 |
Restlessness | 14.87 | 12.00 | 49 | 32437 | 39736 | 64426510 |
Restless legs syndrome | 14.81 | 12.00 | 29 | 32457 | 17087 | 64449159 |
Type 2 diabetes mellitus | 14.64 | 12.00 | 44 | 32442 | 33976 | 64432270 |
Haemoptysis | 14.55 | 12.00 | 56 | 32430 | 48992 | 64417254 |
Anxiety | 14.50 | 12.00 | 161 | 32325 | 202488 | 64263758 |
Infective exacerbation of chronic obstructive airways disease | 14.35 | 12.00 | 11 | 32475 | 2427 | 64463819 |
Arthralgia | 14.33 | 12.00 | 148 | 32338 | 442112 | 64024134 |
Lip pruritus | 14.23 | 12.00 | 7 | 32479 | 698 | 64465548 |
Arthritis allergic | 14.10 | 12.00 | 3 | 32483 | 17 | 64466229 |
Coma | 14.07 | 12.00 | 14 | 32472 | 87601 | 64378645 |
Oral candidiasis | 14.00 | 12.00 | 34 | 32452 | 23178 | 64443068 |
Neutropenic sepsis | 13.94 | 12.00 | 34 | 32452 | 23238 | 64443008 |
Paranasal sinus mucosal hypertrophy | 13.92 | 12.00 | 4 | 32482 | 87 | 64466159 |
Drug hypersensitivity | 13.90 | 12.00 | 67 | 32419 | 237748 | 64228498 |
Intentional overdose | 13.74 | 12.00 | 15 | 32471 | 89929 | 64376317 |
Fungal infection | 13.53 | 12.00 | 43 | 32443 | 34208 | 64432038 |
Orthostatic intolerance | 13.52 | 12.00 | 9 | 32477 | 1591 | 64464655 |
Swelling face | 13.24 | 12.00 | 62 | 32424 | 59104 | 64407142 |
Acute kidney injury | 13.10 | 12.00 | 154 | 32332 | 449086 | 64017160 |
Mouth ulceration | 13.07 | 12.00 | 41 | 32445 | 32403 | 64433843 |
Osteopenia | 13.05 | 12.00 | 26 | 32460 | 15514 | 64450732 |
Tracheo-oesophageal fistula | 13.04 | 12.00 | 6 | 32480 | 515 | 64465731 |
Bone marrow failure | 12.97 | 12.00 | 4 | 32482 | 47948 | 64418298 |
Therapeutic product effect decreased | 12.90 | 12.00 | 24 | 32462 | 115327 | 64350919 |
Psoriatic arthropathy | 12.86 | 12.00 | 3 | 32483 | 43278 | 64422968 |
Pancreatitis relapsing | 12.78 | 12.00 | 7 | 32479 | 871 | 64465375 |
Hypertension | 12.66 | 12.00 | 192 | 32294 | 259069 | 64207177 |
Spirometry abnormal | 12.47 | 12.00 | 6 | 32480 | 570 | 64465676 |
Nocturnal dyspnoea | 12.45 | 12.00 | 8 | 32478 | 1334 | 64464912 |
Device ineffective | 12.40 | 12.00 | 4 | 32482 | 130 | 64466116 |
Mobility decreased | 12.37 | 12.00 | 15 | 32471 | 85825 | 64380421 |
Plasma cell myeloma | 12.18 | 12.00 | 4 | 32482 | 46071 | 64420175 |
Death | 12.03 | 12.00 | 171 | 32315 | 482534 | 63983712 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Congenital naevus | 27.57 | 16.44 | 5 | 6 | 70 | 84597 |
Source | Code | Description |
---|---|---|
ATC | R03AC13 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists |
ATC | R03AK07 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AK08 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AK09 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AK11 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AL05 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03AL07 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03AL09 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03AL10 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03AL11 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03CC15 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Selective beta-2-adrenoreceptor agonists |
FDA MoA | N0000009922 | Adrenergic beta2-Agonists |
CHEBI has role | CHEBI:35522 | beta-adrenergic agonists |
CHEBI has role | CHEBI:35523 | bronchodilator |
CHEBI has role | CHEBI:49167 | anti-asthmatic drugs |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D000322 | Adrenergic Agonists |
MeSH PA | D058666 | Adrenergic beta-2 Receptor Agonists |
MeSH PA | D000318 | Adrenergic beta-Agonists |
MeSH PA | D018927 | Anti-Asthmatic Agents |
MeSH PA | D001993 | Bronchodilator Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D019141 | Respiratory System Agents |
FDA EPC | N0000175779 | beta2-Adrenergic Agonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pulmonary emphysema | indication | 87433001 | |
Non-allergic asthma | indication | 266361008 | DOID:9360 |
Severe chronic obstructive pulmonary disease | indication | 313299006 | |
Allergic asthma | indication | 389145006 | DOID:9415 |
Adjunct Therapy to Achieve Long-term Asthma Control | indication | ||
Exercise-Induced Bronchospasm Prevention | indication | ||
COPD Associated with Chronic Bronchitis | indication | ||
Bronchospasm Prevention with COPD | indication | ||
Mycosis | contraindication | 3218000 | DOID:1564 |
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Asthenia | contraindication | 13791008 | |
Measles | contraindication | 14189004 | DOID:8622 |
Disease caused by parasite | contraindication | 17322007 | |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Acute tuberculosis | contraindication | 25629007 | |
Immunosuppression | contraindication | 38013005 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Varicella | contraindication | 38907003 | DOID:8659 |
Hypokalemia | contraindication | 43339004 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Osteoporosis | contraindication | 64859006 | DOID:11476 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hypopituitarism | contraindication | 74728003 | DOID:9406 |
Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
Bilateral cataracts | contraindication | 95722004 | |
Prolonged QT interval | contraindication | 111975006 | |
Seizure disorder | contraindication | 128613002 | |
Ophthalmic herpes simplex | contraindication | 186542001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Exacerbation of asthma | contraindication | 281239006 | |
Osteopenia | contraindication | 312894000 | |
Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
Congenital long QT syndrome | contraindication | 442917000 | |
Uncontrolled Bacterial Infections | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.23 | acidic |
pKa2 | 12.47 | acidic |
pKa3 | 8.49 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 10166247 | Jan. 29, 2023 | USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 10166247 | Jan. 29, 2023 | USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 10166247 | Jan. 29, 2023 | USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 7759328 | Jan. 29, 2023 | USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 7759328 | Jan. 29, 2023 | USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 7759328 | Jan. 29, 2023 | USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8143239 | Jan. 29, 2023 | USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8143239 | Jan. 29, 2023 | USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8143239 | Jan. 29, 2023 | USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8575137 | Jan. 29, 2023 | USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8575137 | Jan. 29, 2023 | USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.08MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8575137 | Jan. 29, 2023 | USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 10166247 | Jan. 29, 2023 | USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 10166247 | Jan. 29, 2023 | USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 10166247 | Jan. 29, 2023 | USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 7759328 | Jan. 29, 2023 | USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 7759328 | Jan. 29, 2023 | USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 7759328 | Jan. 29, 2023 | USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8143239 | Jan. 29, 2023 | USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8143239 | Jan. 29, 2023 | USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8143239 | Jan. 29, 2023 | USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8575137 | Jan. 29, 2023 | USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8575137 | Jan. 29, 2023 | USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
0.16MG/INH;0.0045MG/INH | SYMBICORT | ASTRAZENECA | N021929 | July 21, 2006 | RX | AEROSOL, METERED | INHALATION | 8575137 | Jan. 29, 2023 | USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER |
0.4MG/INH;0.012MG/INH | DUAKLIR PRESSAIR | COVIS | N210595 | March 29, 2019 | RX | POWDER, METERED | INHALATION | RE46417 | Feb. 10, 2025 | MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.4MG/INH;0.012MG/INH | DUAKLIR PRESSAIR | COVIS | N210595 | March 29, 2019 | RX | POWDER, METERED | INHALATION | 10085974 | March 13, 2029 | MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.4MG/INH;0.012MG/INH | DUAKLIR PRESSAIR | COVIS | N210595 | March 29, 2019 | RX | POWDER, METERED | INHALATION | 11000517 | March 13, 2029 | MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.0048MG/INH;0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 10716753 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.0048MG/INH;0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 8324266 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.0048MG/INH;0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 8703806 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.0048MG/INH;0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 8808713 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.0048MG/INH;0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 9415009 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.0048MG/INH;0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 9463161 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.16MG/INH;0.0048MG/INH;0.009MG/INH | BREZTRI AEROSPHERE | ASTRAZENECA AB | N212122 | July 23, 2020 | RX | AEROSOL, METERED | INHALATION | 10716753 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.16MG/INH;0.0048MG/INH;0.009MG/INH | BREZTRI AEROSPHERE | ASTRAZENECA AB | N212122 | July 23, 2020 | RX | AEROSOL, METERED | INHALATION | 8324266 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.16MG/INH;0.0048MG/INH;0.009MG/INH | BREZTRI AEROSPHERE | ASTRAZENECA AB | N212122 | July 23, 2020 | RX | AEROSOL, METERED | INHALATION | 8703806 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.16MG/INH;0.0048MG/INH;0.009MG/INH | BREZTRI AEROSPHERE | ASTRAZENECA AB | N212122 | July 23, 2020 | RX | AEROSOL, METERED | INHALATION | 8808713 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.16MG/INH;0.0048MG/INH;0.009MG/INH | BREZTRI AEROSPHERE | ASTRAZENECA AB | N212122 | July 23, 2020 | RX | AEROSOL, METERED | INHALATION | 9415009 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.16MG/INH;0.0048MG/INH;0.009MG/INH | BREZTRI AEROSPHERE | ASTRAZENECA AB | N212122 | July 23, 2020 | RX | AEROSOL, METERED | INHALATION | 9463161 | May 28, 2030 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.0048MG/INH;0.0090MG/INH | BEVESPI AEROSPHERE | ASTRAZENECA | N208294 | April 25, 2016 | RX | AEROSOL, METERED | INHALATION | 8815258 | March 17, 2031 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
0.16MG/INH;0.0048MG/INH;0.009MG/INH | BREZTRI AEROSPHERE | ASTRAZENECA AB | N212122 | July 23, 2020 | RX | AEROSOL, METERED | INHALATION | 8815258 | March 17, 2031 | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
0.4MG/INH;0.012MG/INH | DUAKLIR PRESSAIR | COVIS | N210595 | March 29, 2019 | RX | POWDER, METERED | INHALATION | March 29, 2022 | NEW COMBINATION |
0.005MG/INH;0.05MG/INH | DULERA | ORGANON | N022518 | Aug. 12, 2019 | RX | AEROSOL, METERED | INHALATION | Aug. 12, 2022 | NEW STRENGTH |
0.005MG/INH;0.05MG/INH | DULERA | ORGANON | N022518 | Aug. 12, 2019 | RX | AEROSOL, METERED | INHALATION | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
0.16MG/INH;0.0048MG/INH;0.009MG/INH | BREZTRI AEROSPHERE | ASTRAZENECA AB | N212122 | July 23, 2020 | RX | AEROSOL, METERED | INHALATION | July 23, 2023 | NEW COMBINATION |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-2 adrenergic receptor | GPCR | AGONIST | Kd | 8.60 | CHEMBL | CHEMBL | |||
D(2) dopamine receptor | GPCR | Ki | 4.89 | CHEMBL | |||||
Beta-1 adrenergic receptor | GPCR | Ki | 6.50 | CHEMBL | |||||
Beta-3 adrenergic receptor | GPCR | EC50 | 7.60 | CHEMBL | |||||
Heat shock protein HSP 90-alpha | Cytosolic other | IC50 | 8.52 | WOMBAT-PK | |||||
D(3) dopamine receptor | GPCR | Ki | 5.79 | CHEMBL | |||||
Beta-2 adrenergic receptor | GPCR | EC50 | 8.80 | CHEMBL |
ID | Source |
---|---|
4021266 | VUID |
N0000148706 | NUI |
D01373 | KEGG_DRUG |
183814-30-4 | SECONDARY_CAS_RN |
4021266 | VANDF |
4021267 | VANDF |
4026240 | VANDF |
C0060657 | UMLSCUI |
CHEBI:5147 | CHEBI |
CHEMBL1256786 | ChEMBL_ID |
CHEMBL3989798 | ChEMBL_ID |
DB00983 | DRUGBANK_ID |
D000068759 | MESH_DESCRIPTOR_UI |
3083544 | PUBCHEM_CID |
3465 | IUPHAR_LIGAND_ID |
4935 | INN_ID |
5ZZ84GCW8B | UNII |
236216 | RXNORM |
15056 | MMSL |
347879 | MMSL |
d04572 | MMSL |
005421 | NDDF |
005422 | NDDF |
016698 | NDDF |
129490002 | SNOMEDCT_US |
386171009 | SNOMEDCT_US |
414289007 | SNOMEDCT_US |
447213002 | SNOMEDCT_US |
CHEMBL2133469 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Dulera | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0085-4610 | AEROSOL | 5 ug | RESPIRATORY (INHALATION) | NDA | 29 sections |
Dulera | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0085-7206 | AEROSOL | 5 ug | RESPIRATORY (INHALATION) | NDA | 29 sections |
Formoterol fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4061 | SOLUTION | 20 ug | RESPIRATORY (INHALATION) | ANDA | 28 sections |
SYMBICORT | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0186-0370 | AEROSOL | 4.50 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
SYMBICORT | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0186-0372 | AEROSOL | 4.50 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
BEVESPI AEROSPHERE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-4600 | AEROSOL, METERED | 4.80 ug | RESPIRATORY (INHALATION) | NDA | 29 sections |
BEVESPI AEROSPHERE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-4600 | AEROSOL, METERED | 4.80 ug | RESPIRATORY (INHALATION) | NDA | 29 sections |
BREZTRI | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0310-4616 | AEROSOL, METERED | 4.80 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
Budesonide and Formoterol Fumarate Dihydrate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-7370 | AEROSOL | 4.50 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 28 sections |
Budesonide and Formoterol Fumarate Dihydrate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-7372 | AEROSOL | 4.50 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 28 sections |
FORMOTEROL FUMARATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1631 | SOLUTION | 20 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 28 sections |
BREYNA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-7502 | AEROSOL, METERED | 4.50 ug | RESPIRATORY (INHALATION) | ANDA | 29 sections |
BREYNA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-7503 | AEROSOL, METERED | 4.50 ug | RESPIRATORY (INHALATION) | ANDA | 29 sections |
Perforomist | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-605 | SOLUTION | 20 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
Dulera | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1916 | AEROSOL | 5 ug | RESPIRATORY (INHALATION) | NDA | 29 sections |
Budesonide and Formoterol Fumarate Dihydrate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53002-2666 | AEROSOL | 4.50 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 29 sections |
Budesonide and Formoterol Fumarate Dihydrate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53002-2667 | AEROSOL | 4.50 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 29 sections |
Formoterol Fumarate | Human Prescription Drug Label | 1 | 62332-655 | SOLUTION | 20 ug | RESPIRATORY (INHALATION) | ANDA | 26 sections |
Formoterol fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8813 | SOLUTION | 20 ug | RESPIRATORY (INHALATION) | ANDA | 28 sections |
Formoterol fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8813 | SOLUTION | 20 ug | RESPIRATORY (INHALATION) | ANDA | 28 sections |
Formoterol fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8814 | SOLUTION | 20 ug | RESPIRATORY (INHALATION) | ANDA | 28 sections |
Formoterol fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8814 | SOLUTION | 20 ug | RESPIRATORY (INHALATION) | ANDA | 28 sections |
SYMBICORT | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70518-2696 | AEROSOL | 4.50 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
Budesonide and Formoterol Fumarate Dihydrate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70518-3107 | AEROSOL | 4.50 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 28 sections |
Budesonide and Formoterol Fumarate Dihydrate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70518-3107 | AEROSOL | 4.50 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 28 sections |
DUAKLIR PRESSAIR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72124-001 | POWDER, METERED | 12 ug | RESPIRATORY (INHALATION) | NDA | 26 sections |
Dulera | HUMAN PRESCRIPTION DRUG LABEL | 2 | 78206-125 | AEROSOL | 5 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
Dulera | HUMAN PRESCRIPTION DRUG LABEL | 2 | 78206-125 | AEROSOL | 5 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
Dulera | HUMAN PRESCRIPTION DRUG LABEL | 2 | 78206-126 | AEROSOL | 5 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |
Dulera | HUMAN PRESCRIPTION DRUG LABEL | 2 | 78206-126 | AEROSOL | 5 ug | RESPIRATORY (INHALATION) | NDA | 28 sections |